Daily News for Dealmakers
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments
Source
Author: unknown
Strategic Investment: CVC Capital Partners targets €700 million fundraising for Genetic, a leading Italian pharmaceutical outsourcing company, to drive organic and inorganic growth. Industry...
Strategic Focus: The merger between AlloVir and Kalaris Therapeutics creates a biotech entity laser-focused on developing innovative treatments for retinal diseases like neovascular age-related...
Strategic Consolidation: AlloVir and Kalaris Therapeutics merge to create a biotech powerhouse focused on retinal disease treatments. Market Potential: The global retinal disease market is projected...
Strategic Acquisition: Boston Scientific's acquisition of Cortex, Inc. expands its electrophysiology portfolio with the OptiMap System, a diagnostic mapping solution for complex atrial fibrillation...